8-K//Current report
Camp4 Therapeutics Corp 8-K
Accession 0001736730-25-000116
$CAMPCIK 0001736730operating
Filed
Dec 22, 7:00 PM ET
Accepted
Dec 23, 4:59 PM ET
Size
153.8 KB
Accession
0001736730-25-000116
Research Summary
AI-generated summary of this filing
Camp4 Therapeutics Enters Watertown Lease, Amends Cambridge Lease
What Happened
- Camp4 Therapeutics (CAMP) announced on December 22, 2025 that it entered into a Lease Agreement for approximately 44,000 rentable sq ft at 100 Talcott Avenue, Watertown, MA (the "Watertown Lease") and simultaneously executed a First Amendment to its existing Cambridge Lease (dated Oct 3, 2019) for ~30,760 sq ft at One Kendall Square.
- The Cambridge Lease’s scheduled expiration was June 30, 2027; the amendment accelerates that termination to an "Early Termination Date" equal to 30 days after the Watertown Lease Commencement Date. Base rent for the Cambridge space will be abated from October 1, 2025 through the Early Termination Date, provided no default occurs.
Key Details
- Watertown Premises: ~44,000 rentable sq ft; initial lease term runs from the Commencement Date through June 30, 2030.
- Base rent: $40.00 per rentable sq ft annually for Watertown, with 3% annual increases; option to extend one 5‑year term at market rent not less than $85.00/rsf.
- Timing & abatements: Commencement is targeted 180 days after the Dec 22, 2025 effective date; base rent obligation typically begins 120 days after Commencement (the Rent Commencement Date), but the company negotiated an Additional Base Rent Abatement Period tied to payment of the Lease Modification Fee.
- Lease Modification Fee: approximately $2.1 million, payable in roughly equal monthly installments over the Additional Base Rent Abatement Period; in return, the company receives additional base-rent abatement at Watertown (subject to no defaults).
Why It Matters
- This transaction shifts Camp4’s primary lab/office footprint from Cambridge (30,760 sq ft) to a larger Watertown facility (44,000 sq ft) under a long-term lease to mid‑2030, which may support the company’s growth or operational needs.
- The company negotiated rent abatements and a staged payment (the ~$2.1M fee) that defer cash rent outflows initially, but the agreement creates a definite cash obligation and future rent and operating expense commitments (including responsibility for a share of operating expenses).
- Investors should note the timing dependencies (actual lease commencement, abatements, and the Early Termination Date) because those affect near-term cash use and when lease expense will begin; full lease documents will be included in Camp4’s 2025 Form 10‑K for more detail.
Note: The Form 8‑K also references Item 1.02 (termination of a material definitive agreement) but the provided excerpt was incomplete — see the filed 8‑K and forthcoming 10‑K exhibits for the complete agreements and any termination details.
Documents
- 8-Kcamp-20251222.htmPrimary
8-K
- EX-101.SCHcamp-20251222.xsd
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
- EX-101.LABcamp-20251222_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
- EX-101.PREcamp-20251222_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
- XMLR1.htm
IDEA: XBRL DOCUMENT
- XMLShow.js
IDEA: XBRL DOCUMENT
- XMLreport.css
IDEA: XBRL DOCUMENT
- XMLFilingSummary.xml
IDEA: XBRL DOCUMENT
- JSONMetaLinks.json
IDEA: XBRL DOCUMENT
- ZIP0001736730-25-000116-xbrl.zip
IDEA: XBRL DOCUMENT
- XMLcamp-20251222_htm.xml
IDEA: XBRL DOCUMENT
Issuer
Camp4 Therapeutics Corp
CIK 0001736730
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001736730
Filing Metadata
- Form type
- 8-K
- Filed
- Dec 22, 7:00 PM ET
- Accepted
- Dec 23, 4:59 PM ET
- Size
- 153.8 KB